You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Advancing Formulation of STING agonist for Universal Flu Vaccine

    SBC: IMMvention Therapeutix, Inc.            Topic: NIAID

    Summary Influenza virusa member of the orthomyxovirus familyhas three different types that infect humansABand CTypes A and B produce annual epidemicsand type A influenzawhich resides asymptomatically in birdscan cause pandemic infections in humansIn addition to common flu like symptomse gfeverchillsmalaisemuscle painin susceptible populations influenza can induce potentially fatal secondary compli ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Amelioration of rhinovirus induced asthma exacerbations by serpin B1

    SBC: SERPLUS TECHNOLOGY LLC            Topic: NIAID

    PROJECT SUMMARY Asthma exacerbations are a major cause of ER visits and hospitalizations with annual direct costs of approximately $billionyear in the USAViral infectionsin particular rhinoviralRVinfectionsare a major precipitant of asthma exacerbations in allergic asthmaticsAs there are overRV serotypes andfor nowno RV vaccinenovel strategies to inhibit RV induced airway inflammation are needed t ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Validation of a Novel Fungicidal Approach for Cryptococcal Meningitis

    SBC: Minnetronix Medical, Inc.            Topic: NIAID

    ABSTRACT When Cryptococcus is manifested as cryptococcal meningitis (CM), it creates a large burden of mortality and morbidity to the patient and is very difficult for the clinician to treat. There are now an estimated 2600-7800 US cases and 400,000 cases of CM worldwide annually, with estimated mortality of 15-50% per year. CM is caused when Cryptococcus neoformans, a basidiomycete fungal pathoge ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Targeting the host response to limit infection by intracellular bacterial pathogens

    SBC: Blue Ridge Biosciences, LLC            Topic: NIAID

    Antibiotic development has traditionally focused on drugs that target the pathogen but resistance inevitably developsAn attractive alternative is to develop drugs that target the host response and in particular for facultative obligate intracellular bacterial pathogenswhich rely on the host for disease progressionIntracellular bacterial pathogens manipulate the host cytoskeletal system to their ad ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Image Analysis Tools for mpMRI Prostate Cancer Diagnosis Using PI-RADS

    SBC: ZMK Medical Technologies, Inc.            Topic: 102

    ABSTRACTProstate cancerPCais one of the most commonly occurring forms of canceraccounting forof all cancer in menMulti parametric magnetic resonance imagingmpMRIhas led to improved capabilities for detectinglocalizingand staging PCaCombined with image guided prostate biopsympMRI has helped to improve diagnosis of clinically significant PCawhich helps to reduce mortality as well as unnecessary biop ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Inter-examiner Agreement of a Novel Device for the Measurement of Cervical Dilation in Labor: A Randomized Controlled Trial

    SBC: Elm Tree Medical Inc.            Topic: NICHD

    Measurement of cervical dilation during late pregnancy and labor informs decisions in the management of labor and deliveryPrior published research suggests that practitioners are onlytoaccurate when judging cervical simulatorsWhen measuring laboring womentwo practitionersandaposmeasurements agree onlyof the timeDrEva Martin of Elm Tree Medical Incdeveloped a novel deviceDilaCheckto enable practiti ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Automated preparation of single-cells and nuclei from solid tissues

    SBC: S2 GENOMICS, INC            Topic: 172

    Project Summary AbstractThis project designsdevelopsand automates a novel system to process solid tissue into single cellssingle nucleiand high molecular weight DNA using disposable cartridges without user interventionThe system will support downstream single cell RNA or DNA sequencingsingle nuclei RNA or DNA sequencingand long read sequencers and optical mappingThe long term goal of the project i ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Microfluidic CAR-T Cell Processing Device

    SBC: GPB Scientific, Inc.            Topic: 101

    ABSTRACT The goal of this Fast Track STTR project is to develop a Deterministic Lateral DisplacementDLDmicrofluidic device that can enrich white blood cellsWBCsfrom a typical leukapheresis unit inhrfor use in manufacturing cancer cellular immunotherapyChimeric antigen receptor T cellCAR Ttherapy has been recommended for FDA approval to treat relapsed or refractory pediatric and young adult patient ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting glioblastoma stem-like cells with custom-designed viral vectors

    SBC: Lacerta Therapeutics, Inc.            Topic: 102

    Abstract GlioblastomaGBMis the most lethal form of adult brain cancers with a median survival of andltmonths despite aggressive standard chemoradiationGBM are formed by GBM stem like cellsGSCsa major contributor to tumor recurrence and a natural focus for therapeutic developmentThere are two main reasons responsible for treatment failurehigh intraand inter tumor cellular and molecular heterogeneit ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100

    SBC: NEONC TECHNOLOGIES INC            Topic: 102

    Project Summary Abstract Many pharmaceutical agents are highly potentbut are unable to exert substantial therapeutic activity against disorders of the brainbecause the blood brain barrierBBBeffectively prevents their access to the site of intracerebral diseaseFor examplethe majority of glioblastoma patientsdespite the best efforts of current medical caredie within two years after diagnosisHencethe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government